US · PHAR · BIOTECHNOLOGY
Pharming Group N.V. (PHAR) intrinsic value and stock valuation
$11.54as of 2026-11-21 · Mkt cap 755.56M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Pharming Group N.V. DCF and intrinsic value
InvestorsCraft values PHAR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PHAR’s statements →
Pharming Group N.V. Graham Number
Graham Number: $1.87d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Tango Therapeutics, Inc. (TNGX) $21.73
- Palvella Therapeutics, Inc. (PVLA) $142.85
- Fortrea Holdings Inc. (FTRE) $18.55
- Septerna Inc (SEPN) $38.61
- Bicara Therapeutics Inc. Common Stock (BCAX) $8.44
- EyePoint Pharmaceuticals, Inc. (EYPT) $0.23
- Arbutus Biopharma Corp (ABUS) $4.02
- Kura Oncology, Inc. (KURA) $6.91
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $376.1M | $307.8M | $245.3M | $205.6M | $225.5M |
| Operating income | $20.9M | -$-8.93M | -$-5.39M | $18.2M | $15.4M |
| Net income | $2.85M | -$-12.26M | -$-10.55M | $13.7M | $18.1M |
| EPSd | $40K | -$-177.89K | -$-160.58K | $162.2K | $206.9K |
| Operating cash flow | $54.7M | -$-1.79M | -$-17.3M | $22.5M | $37.8M |
| Capital expenditure | -$-760K | -$-800K | -$-1.46M | -$-1.98M | -$-16.72M |
| Free cash flow | $54M | -$-2.59M | -$-18.77M | $20.5M | $21.1M |
| Total assets | $499.8M | $414.2M | $462.9M | $425.8M | $450.4M |
| Total debt | $115.8M | $116.3M | $171.5M | $166.7M | $183.4M |
| Net debt | -$-30.25M | $59.4M | $109.8M | -$-40.65M | -$-34.2M |
| Total equity | $277M | $228.9M | $218.8M | $204.6M | $218.7M |
| Cash and short-term investments | $179.8M | $173.9M | $213.4M | $207.3M | $217.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $376.1M | $307.8M | $245.3M | $205.6M | $225.5M |
| Cost of revenue | $45.5M | $36.7M | $25.2M | $17.6M | $24M |
| Gross profit | $330.6M | $271.1M | $220.1M | $188.1M | $201.5M |
| Research and development expenses | $100.4M | $86.1M | $68.9M | $52.5M | $79.8M |
| Selling, general and administrative expenses | $117.4M | $102.7M | $87.5M | $68.9M | $54.6M |
| Other expenses | $92M | $91.2M | $69.1M | $48.4M | $51.8M |
| Operating expenses | $309.8M | $280M | $225.5M | $169.8M | $186.1M |
| Cost and expenses | $355.3M | $316.7M | $250.7M | $187.4M | $210.1M |
| Interest income | $2.18M | $5.92M | $3.53M | $90K | $60K |
| Interest expense | $10.7M | $9.05M | $5.96M | $5.36M | $7M |
| Depreciation and amortization | $11.2M | $16.6M | $15.9M | $13.2M | $22.2M |
| Ebitda | $34.8M | $16.9M | $9.88M | $33.5M | $55.3M |
| Operating income | $20.9M | -$-8.93M | -$-5.39M | $18.2M | $15.4M |
| Total other income/expenses, net | -$-8.03M | $130K | -$-6.62M | -$-3.25M | $10.8M |
| Income before tax | $12.9M | -$-8.79M | -$-12.01M | $15M | $26.2M |
| Income tax expense | $10.3M | $3.47M | -$-1.46M | $1.31M | $8.03M |
| Net income | $2.85M | -$-12.26M | -$-10.55M | $13.7M | $18.1M |
| Weighted average shares outstanding | $71.3M | $68.9M | $65.7M | $82.5M | $87.6M |
| Weighted average diluted shares outstanding | $71.3M | $68.9M | $65.7M | $84.3M | $87.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $179.8M | $173.9M | $213.4M | $207.3M | $217.6M |
| Net receivables | $54.7M | $52M | $42.6M | $25.3M | $31.3M |
| Inventory | $64.9M | $57.7M | $56.8M | $42.3M | $31M |
| Total current assets | $299.4M | $288.3M | $316.3M | $277.5M | $282.8M |
| Property, plant and equipment, net | $24M | $24.1M | $33.5M | $39.2M | $37.6M |
| Goodwill and intangible assets | $135.5M | $63.2M | $71.3M | $75.1M | $95M |
| Long-term investments | $9.87M | $4.38M | $10.4M | $9.73M | $9.81M |
| Total non-current assets | $200.4M | $125.9M | $146.5M | $148.3M | $167.6M |
| Total assets | $499.8M | $414.2M | $462.9M | $425.8M | $450.4M |
| Accounts payable | $105.9M | $10.5M | $16M | $8.75M | $8.62M |
| Short-term debt | $8.71M | $7.45M | $5.44M | $5.23M | $4.87M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $115.8M | $76.4M | $78M | $59.7M | $53M |
| Long-term debt | $107.1M | $108.9M | $166.1M | $161.5M | $178.5M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $107.1M | $108.9M | $166.1M | $161.5M | $178.7M |
| Capital lease obligations | $17.7M | $31M | $33.1M | $33.3M | $23.7M |
| Total liabilities | $222.8M | $185.3M | $244.1M | $221.2M | $231.7M |
| Common stock | $8.01M | $8.04M | $7.67M | $7.51M | $8.42M |
| Retained earnings | -$-272.9M | -$-285.27M | -$-265.26M | -$-256.43M | -$-309.69M |
| Accumulated other comprehensive income (loss) | $0.00 | -$-220K | -$-2.06M | -$-8.74M | $3.85M |
| Total equity | $277M | $228.9M | $218.8M | $204.6M | $218.7M |
| Total investments | $43.7M | $121.3M | $162.1M | $9.73M | $9.81M |
| Total debt | $115.8M | $116.3M | $171.5M | $166.7M | $183.4M |
| Net debt | -$-30.25M | $59.4M | $109.8M | -$-40.65M | -$-34.2M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $12.9M | -$-8.49M | -$-12.01M | $15M | $23.1M |
| Depreciation and amortization | $11.2M | $16.1M | $15.9M | $13.2M | $19.6M |
| Stock-based compensation | $13.8M | $11.3M | $9.25M | $6.39M | $9.06M |
| Change in working capital | $10.4M | -$-10.07M | -$-16.96M | -$-390K | -$-4.96M |
| Accounts receivable | -$-3.35M | -$-6.78M | -$-18.54M | $2.36M | $5.92M |
| Inventory | -$-1.29M | -$-500K | -$-14.43M | -$-15.02M | -$-6.15M |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | $54.7M | -$-1.79M | -$-17.3M | $22.5M | $37.8M |
| Investments in property, plant and equipment | -$-760K | -$-800K | -$-1.46M | -$-1.98M | -$-16.72M |
| Acquisitions, net | -$-58.22M | $0.00 | $0.00 | $7.3M | $0.00 |
| Net cash used for investing activities | $26.3M | $31.6M | -$-129.39M | $5.32M | -$-21.3M |
| Common stock issued | $19.8M | $5.58M | $8.13M | $2.28M | $4.72M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $1.5M | -$-34.41M | -$-1.04M | -$-4.98M | -$-27.95M |
| Net change in cash | $90.4M | -$-6.8M | -$-145.6M | $15.4M | -$-13.23M |
| Cash at end of period | $145.3M | $54.9M | $61.7M | $207.3M | $191.9M |
| Operating cash flow | $54.7M | -$-1.79M | -$-17.3M | $22.5M | $37.8M |
| Capital expenditure | -$-760K | -$-800K | -$-1.46M | -$-1.98M | -$-16.72M |
| Free cash flow | $54M | -$-2.59M | -$-18.77M | $20.5M | $21.1M |
Line items
Line items
Line items
About Pharming Group N.V.
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
- CEO
- Fabrice Chouraqui
- Employees
- 407
- Beta
- 0.09
Explore
Frequently asked questions
What is the intrinsic value of Pharming Group N.V. (PHAR)?
InvestorsCraft does not currently publish an intrinsic value for PHAR. How the IC value is calculated.
Is PHAR undervalued?
InvestorsCraft does not publish an undervaluation signal for PHAR at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.